Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference Pharmaceutical Investing
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies Medical Device Investing
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York Pharmaceutical Investing
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate Life Science Investing
U.S. FDA Accepts for Review the Biologics License Application for Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate in Adolescents Life Science Investing
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Pharmaceutical Investing
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
